First-of-its-kind technology provides individualized, actionable insights on dose and interval for infliximab

Prometheus Laboratories recently announced the launch of PredictrPK IFX, which uses a machine learning algorithm to combine patient weight, current dose and interval, measured serum IFX, measured antibodies-to-infliximab and albumin levels to predict optimal, individualized infliximab dosing. This new technology can help validate existing treatment plans or investigate alternative doses and intervals.

Read the full press release from Prometheus Laboratories here: https://www.prometheuslabs.com/about_predictrpk/